Cell & Gene
Cell & Gene Therapies: An Overview Of FDA Regulatory Considerations For 2024
April 17, 2024
In an explicit effort to bring approved cell and gene therapies (CGT) to patients sooner, FDA has launched a number of initiatives and programs to address the pace of CGT approvals. In this article for Cell & Gene, Sidley’s Emily Marden and Kelly Cho share their insights on key regulatory developments relevant to sponsors seeking regulatory approval of CGTs for commercialization in the U.S.
View article here.
Contacts
Capabilities
Suggested News & Insights
Recharge & Recaffeinate with Sidley @ JPMMonday, January 12, 2026 – Tuesday, January 13, 2026Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch @ JPM 2026Monday, January 12, 2026Connecting Clusters of Excellence: Europe as Your Gateway to Global Success – Organized by Biovia, Health Campus Limburg DC, SidleyMonday, January 12, 2026#DrugPricing: More Average Sales Price Proposals and New Comment PeriodJanuary 6, 2026EU Pharma Package: Sharp New Tools With Limited ProtectionsDecember 18, 2025First Chair Trial and Leading Product Liability Lawyer Paul Boehm Joins Sidley as Partner in D.C. to Expand Product Liability and Mass Torts Litigation PracticeDecember 18, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory